logo
  

Bottomline Technologies Q1 Loss Narrows

Bottomline Technologies Inc. (EPAY), a provider of cloud-based payment sevices, Thursday reported a smaller loss for the first quarter, as revenues jumped 21 percent. Both adjusted earnings and revenues for the quarter trumped Wall Street analysts' estiamtes.

The Portsmouth, New Hampshire-based company's first-quarter loss of $3.27 million or $0.09 per share, narrower than last year's loss of $6.05 million or $0.17 per share.

Core net income, which exclude one-time items, for the quarter rose to $13.92 million or $0.37 per share from $10.20 million or $0.28 per share last year. On average, eight analysts polled by Thomson Reuters expected earnings of $0.33 per share for the quarter. Analysts' estimates typically exclude special items.

Revenues for the first quarter rose 21 percent to $81.34 million from $67.25 million last year. Analysts had a consensus revenue estimate of $80.19 million for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT